All In Biotech

Drug Trial Radar · NCT00133848

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adults and Paediatric Subjects With Impetigo.

Last checked: Nov 20, 2026Latest source record: Sep 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

Apr 2005

Primary completion

Not stated

Study completion Jan 2006

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 24, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 9 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.

Conditions

  • Impetigo

Interventions

  • SB-275833 ointment, 1%Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical response of impetigo at end of therapy visit. Clinical response of success is defined as no further need for antibacterial treatment.

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bangalore, India

  • GSK Investigational Site

    Hyderabad, India

  • GSK Investigational Site

    Rome, Lazio, Italy

  • GSK Investigational Site

    Mexico City, Mexico

  • GSK Investigational Site

    Zapopan, Jalisco, Jalisco, Mexico

  • GSK Investigational Site

    Beek en Donk, Netherlands

  • GSK Investigational Site

    Deurne, Netherlands

  • GSK Investigational Site

    Ermelo, Netherlands

  • GSK Investigational Site

    Gouda, Netherlands

  • GSK Investigational Site

    Musselkanaal, Netherlands

  • GSK Investigational Site

    Musselkanaal, Netherlands

  • GSK Investigational Site

    Nijmegen, Netherlands

  • GSK Investigational Site

    Nijverdal, Netherlands

  • GSK Investigational Site

    Roelofarendsveen, Netherlands

  • GSK Investigational Site

    Rotterdam, Netherlands

  • GSK Investigational Site

    Rotterdam, Netherlands

  • GSK Investigational Site

    Soerendonk, Netherlands

  • GSK Investigational Site

    Woerden, Netherlands

  • GSK Investigational Site

    Zieuwent, Netherlands

  • GSK Investigational Site

    Zwijndrecht, Netherlands

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Callao, Provincia Constitucional del Callao, Peru

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.